Novo Nordisk Files For EU Approval of Obesity Drug
By Dominic Chopping
Danish pharmaceutical company Novo Nordisk AS said Friday that
it has filed for European Union regulatory approval of its
semaglutide weight-loss drug.
The company has submitted a Marketing Authorisation Application
to the European Medicines Agency for semaglutide as a treatment for
obese or overweight adults in conjunction with a reduced-calorie
diet and increased physical activity.
Novo Nordisk earlier this month submitted a new drug application
to the U.S. Food and Drug Administration for the drug.
"It is a milestone for Novo Nordisk but more importantly it
represents a new treatment option with the potential to transform
the medical management for people living with obesity in Europe,"
Novo Nordisk Chief Scientific Officer Mads Krogsgaard Thomsen
Semaglutide is a glucagon-like peptide-1 drug, or GLP-1, that
helps enhance the production of insulin and regulate appetite.
Write to Dominic Chopping at firstname.lastname@example.org
(END) Dow Jones Newswires
December 18, 2020 04:51 ET (09:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.